Nature research paper: Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
https://go.nature.com/3RjmFHN
https://go.nature.com/3RjmFHN
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation - Nature
Simultaneous inhibition of LSD1 and GSK3 kinase promotes cell differentiation, providing a therapeutic strategy for treating acute myeloid leukaemia.
go.nature.com
April 21, 2025 at 2:31 PM
Nature research paper: Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
https://go.nature.com/3RjmFHN
https://go.nature.com/3RjmFHN
Featured in IJOS's [Top 5 Articles in the first half of 2025]🥳：LSD1 is a protein that promotes cancer. Recent study shows inhibiting LSD1 can reverse early cancer changes and boost immune response, offering a new strategy for oral cancer treatment！👍
#LSD1 #cancer
www.nature.com/articles/s41...
#LSD1 #cancer
www.nature.com/articles/s41...
September 23, 2025 at 2:28 AM
Featured in IJOS's [Top 5 Articles in the first half of 2025]🥳：LSD1 is a protein that promotes cancer. Recent study shows inhibiting LSD1 can reverse early cancer changes and boost immune response, offering a new strategy for oral cancer treatment！👍
#LSD1 #cancer
www.nature.com/articles/s41...
#LSD1 #cancer
www.nature.com/articles/s41...
Engineered LSD1 mutant Y391K bypasses H3K14 acetylation inhibition on K4 demethylation. Study in K562 cells deciphers epigenetic crosstalk. #EpigeneticsInsights PMID:38965385, Nat Chem Biol 2025, @nchembio @Harvard https://doi.org/10.1038/s41589-024-01671-9 #Medsky 🧪
Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1 | Nature Chemical Biology
Biochemical crosstalk between two or more histone modifications is often observed in epigenetic enzyme regulation, but its functional significance in cells has been difficult to discern. Previous enzymatic studies revealed that Lys14 acetylation of histone H3 can inhibit Lys4 demethylation by lysine-specific demethylase 1 (LSD1). In the present study, we engineered a mutant form of LSD1, Y391K, which renders the nucleosome demethylase activity of LSD1 insensitive to Lys14 acetylation. K562 cells with the Y391K LSD1 CRISPR knockin show decreased expression of a set of genes associated with cellular adhesion and myeloid leukocyte activation. Chromatin profiling revealed that the cis-regulatory regions of these silenced genes display a higher level of H3 Lys14 acetylation, and edited K562 cells show diminished H3 mono-methyl Lys4 near these silenced genes, consistent with a role for enhanced LSD1 demethylase activity. These findings illuminate the functional consequences of disconnecting
doi.org
March 6, 2025 at 10:10 AM
Engineered LSD1 mutant Y391K bypasses H3K14 acetylation inhibition on K4 demethylation. Study in K562 cells deciphers epigenetic crosstalk. #EpigeneticsInsights PMID:38965385, Nat Chem Biol 2025, @nchembio @Harvard https://doi.org/10.1038/s41589-024-01671-9 #Medsky 🧪
Engineered LSD1 demethylase sidesteps acetylation, paving new paths to explore histone modifications. Dive deep #Epigenetics! 🧬🔍 PMID:39198575, Nat Chem Biol 2025, @nchembio @ChemEurope https://doi.org/10.1038/s41589-024-01710-5 #Medsky 🧪
Coaching LSD1 to ignore acetylation | Nature Chemical Biology
Engineered demethylase LSD1 opens a new avenue in developing tools to study intricate relationships between histone post-translational modifications that can be enzymatically edited.
doi.org
March 8, 2025 at 6:10 AM
Engineered LSD1 demethylase sidesteps acetylation, paving new paths to explore histone modifications. Dive deep #Epigenetics! 🧬🔍 PMID:39198575, Nat Chem Biol 2025, @nchembio @ChemEurope https://doi.org/10.1038/s41589-024-01710-5 #Medsky 🧪
Discovery of an LSD1 PROTAC degrader
Discovery of an LSD1 PROTAC degrader | PNAS
Aberrant expression of lysine-specific demethylase 1 (LSD1) has been implicated in
various cancers, including acute myeloid leukemia (AML). Recent ...
www.pnas.org
June 6, 2025 at 11:00 AM
Discovery of an LSD1 PROTAC degrader
very excited to be leading this upcoming study looking at HMA +/- the LSD1 inhibitor iadademstat in accelerated/blast-phase MPNs!
clinicaltrials.gov/study/NCT066...
clinicaltrials.gov/study/NCT066...
December 18, 2024 at 8:05 PM
very excited to be leading this upcoming study looking at HMA +/- the LSD1 inhibitor iadademstat in accelerated/blast-phase MPNs!
clinicaltrials.gov/study/NCT066...
clinicaltrials.gov/study/NCT066...
Una de las mejores versiones de Nirvana ever made.
Desde Finlandia y en clave bluegrass.
www.youtube.com/watch?v=lsD1...
Desde Finlandia y en clave bluegrass.
www.youtube.com/watch?v=lsD1...
Steve 'n' Seagulls - In Bloom
YouTube video by Fredi Furi
www.youtube.com
March 4, 2025 at 3:20 PM
Una de las mejores versiones de Nirvana ever made.
Desde Finlandia y en clave bluegrass.
www.youtube.com/watch?v=lsD1...
Desde Finlandia y en clave bluegrass.
www.youtube.com/watch?v=lsD1...
Very excited to be in Barcelona to share our latest data on how LSD1 is a critical target in the Alzheimer’s disease pathway at the Neurobiology of Brain Disorders GRC
August 2, 2026 at 4:31 AM
Very excited to be in Barcelona to share our latest data on how LSD1 is a critical target in the Alzheimer’s disease pathway at the Neurobiology of Brain Disorders GRC
In collaboration with @mattevilab.bsky.social, we share in @naturecomms.bsky.social our work studying the mechanism of LSD1 covalent ‘formylators’. Many LSD1 inhibitors create a bulky FAD-drug adduct. Discovered by Takeda by phenotypic screening, these formylators serendipitously create formyl-FAD.
April 3, 2025 at 12:00 PM
In collaboration with @mattevilab.bsky.social, we share in @naturecomms.bsky.social our work studying the mechanism of LSD1 covalent ‘formylators’. Many LSD1 inhibitors create a bulky FAD-drug adduct. Discovered by Takeda by phenotypic screening, these formylators serendipitously create formyl-FAD.
New preprint from us.
The study led by Mukund Sharma demonstrates how #PP2A mediated dephosphorylation of serine 166 of LSD1 functions as a phosphorylation switch between gene repression and activation by LSD1 and how this shapes tumor microenvironment.
www.biorxiv.org/content/10.1...
The study led by Mukund Sharma demonstrates how #PP2A mediated dephosphorylation of serine 166 of LSD1 functions as a phosphorylation switch between gene repression and activation by LSD1 and how this shapes tumor microenvironment.
www.biorxiv.org/content/10.1...
May 18, 2025 at 2:57 PM
New preprint from us.
The study led by Mukund Sharma demonstrates how #PP2A mediated dephosphorylation of serine 166 of LSD1 functions as a phosphorylation switch between gene repression and activation by LSD1 and how this shapes tumor microenvironment.
www.biorxiv.org/content/10.1...
The study led by Mukund Sharma demonstrates how #PP2A mediated dephosphorylation of serine 166 of LSD1 functions as a phosphorylation switch between gene repression and activation by LSD1 and how this shapes tumor microenvironment.
www.biorxiv.org/content/10.1...
Delighted that my lab could contribute to this beautiful story by Jukka Westermarck's lab www.biorxiv.org/content/10.1...
LSD1 serine 166 is a phosphorylation switch for chromatin landscaping, gene activation, and tissue remodeling
LSD1 is a histone 3 (H3) demethylase that can either repress or activate gene expression. We discover here that the so far enigmatic balance between these two activities in non-hormonal cancer cells i...
www.biorxiv.org
May 19, 2025 at 6:04 PM
Delighted that my lab could contribute to this beautiful story by Jukka Westermarck's lab www.biorxiv.org/content/10.1...
While catching up with literature, here's a bispecific paper "Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers" pubs.acs.org/doi/10.1021/... Is there a review on target relationships for bispecifics - e.g paralog targeted, unrelated etc?
Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers
Epigenetic changes, such as LSD1 dysregulation, contribute to acquired resistance in EGFR mutant NSCLCs and reduce the effectiveness of current therapeutics. To address the challenges, we herein repor...
pubs.acs.org
March 3, 2025 at 2:06 PM
While catching up with literature, here's a bispecific paper "Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers" pubs.acs.org/doi/10.1021/... Is there a review on target relationships for bispecifics - e.g paralog targeted, unrelated etc?
“LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming”
This study defines LSD1 as a critical epigenetic-metabolic regulator in #PDAC whose therapeutic targeting requires subtype stratification ⤵️
www.nature.com/articles/s41...
This study defines LSD1 as a critical epigenetic-metabolic regulator in #PDAC whose therapeutic targeting requires subtype stratification ⤵️
www.nature.com/articles/s41...
LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming - Cell Death & Disease
Cell Death & Disease - LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming
www.nature.com
August 4, 2026 at 9:52 AM
“LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming”
This study defines LSD1 as a critical epigenetic-metabolic regulator in #PDAC whose therapeutic targeting requires subtype stratification ⤵️
www.nature.com/articles/s41...
This study defines LSD1 as a critical epigenetic-metabolic regulator in #PDAC whose therapeutic targeting requires subtype stratification ⤵️
www.nature.com/articles/s41...
@biorxivpreprint.bsky.social LSD1 ablation promotes mammary tumor metastasis by attenuating NK cell-mediated anti-tumor immunity
www.biorxiv.org/content/10.6... @harvardmed.bsky.social
www.biorxiv.org/content/10.6... @harvardmed.bsky.social
March 16, 2026 at 4:16 PM
@biorxivpreprint.bsky.social LSD1 ablation promotes mammary tumor metastasis by attenuating NK cell-mediated anti-tumor immunity
www.biorxiv.org/content/10.6... @harvardmed.bsky.social
www.biorxiv.org/content/10.6... @harvardmed.bsky.social
The basis for our current ANR-DFG project with Gerald Späth: Leishmania manipulate host macrophage epigenetics, via histone demethylase LSD1. @agencerecherche.bsky.social @dfg.de @pasteur.fr #epigenetics @biorxiv-neursci.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Inhibition of the macrophage demethylase LSD1 reverses Leishmania amazonensis-induced transcriptomic changes and causes a decrease in parasite load
Intracellular pathogens exploit host cell functions to favor their own survival. In recent years, the subversion of epigenetic regulation has emerged as a key microbial strategy to modify host cell ge...
www.biorxiv.org
September 26, 2025 at 7:54 AM
The basis for our current ANR-DFG project with Gerald Späth: Leishmania manipulate host macrophage epigenetics, via histone demethylase LSD1. @agencerecherche.bsky.social @dfg.de @pasteur.fr #epigenetics @biorxiv-neursci.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Revealing lysine-specific histone demethylase 1a as a new target for kidney diseases
Tobias B. Huber & team show LSD1 regulates kidney development, and its dysfunction disrupts key kidney cells, leading to cyst formation in mouse and organoid models: doi.org/10.1172/jci....
Tobias B. Huber & team show LSD1 regulates kidney development, and its dysfunction disrupts key kidney cells, leading to cyst formation in mouse and organoid models: doi.org/10.1172/jci....
March 20, 2026 at 11:02 AM
Revealing lysine-specific histone demethylase 1a as a new target for kidney diseases
Tobias B. Huber & team show LSD1 regulates kidney development, and its dysfunction disrupts key kidney cells, leading to cyst formation in mouse and organoid models: doi.org/10.1172/jci....
Tobias B. Huber & team show LSD1 regulates kidney development, and its dysfunction disrupts key kidney cells, leading to cyst formation in mouse and organoid models: doi.org/10.1172/jci....
A novel PROTAC molecule selectively degrades LSD1, a histone demethylase, and disrupts core transcriptional circuitry in AML. This strategy abrogates leukemogenic programs and impairs clonogenic potential in vitro and in xenografts.
PNAS: www.pnas.org/doi/10.1073/...
PNAS: www.pnas.org/doi/10.1073/...
Discovery of an LSD1 PROTAC degrader | PNAS
Aberrant expression of lysine-specific demethylase 1 (LSD1) has been implicated in
various cancers, including acute myeloid leukemia (AML). Recent ...
www.pnas.org
May 15, 2025 at 2:05 AM
A novel PROTAC molecule selectively degrades LSD1, a histone demethylase, and disrupts core transcriptional circuitry in AML. This strategy abrogates leukemogenic programs and impairs clonogenic potential in vitro and in xenografts.
PNAS: www.pnas.org/doi/10.1073/...
PNAS: www.pnas.org/doi/10.1073/...
📣 Big news ahead of JPM: 2 of our key investigational oncology drugs have received regulatory approval to advance to clinical trials: REC-4539 – potential best-in-class LSD1 inhibitor for SCLC & other indications & REC-3565 – a potential best-in-class MALT1 inhibitor for B-cell malignancies. 🧵
January 7, 2025 at 2:22 PM
📣 Big news ahead of JPM: 2 of our key investigational oncology drugs have received regulatory approval to advance to clinical trials: REC-4539 – potential best-in-class LSD1 inhibitor for SCLC & other indications & REC-3565 – a potential best-in-class MALT1 inhibitor for B-cell malignancies. 🧵
Huge pleasure for me and Tim Chevassut to host Prof Yang Shi from @ludwigcancer.bsky.social @ox.ac.uk for a @biochembiomeduos.bsky.social @bsmsmedschool.bsky.social research seminar on his pioneering work dual targeting LSD1 and GSK in AML, and epigenetic dysregulation in diffuse midline glioma.
September 17, 2025 at 7:43 AM
Huge pleasure for me and Tim Chevassut to host Prof Yang Shi from @ludwigcancer.bsky.social @ox.ac.uk for a @biochembiomeduos.bsky.social @bsmsmedschool.bsky.social research seminar on his pioneering work dual targeting LSD1 and GSK in AML, and epigenetic dysregulation in diffuse midline glioma.
LSD1 ablation promotes mammary tumor metastasis by attenuating NK cell-mediated anti-tumor immunity https://www.biorxiv.org/content/10.64898/2026.03.12.711410v1
March 15, 2026 at 1:48 PM
LSD1 ablation promotes mammary tumor metastasis by attenuating NK cell-mediated anti-tumor immunity https://www.biorxiv.org/content/10.64898/2026.03.12.711410v1
#DBfeature #Zebrafish🐟 #EHT
LSD1 promotes the egress of hematopoietic stem and progenitor cells into the bloodstream during the endothelial-to-hematopoietic transition
by Junya Tamaoki, Makoto Kobayashi et al
www.sciencedirect.com/science/arti...
LSD1 promotes the egress of hematopoietic stem and progenitor cells into the bloodstream during the endothelial-to-hematopoietic transition
by Junya Tamaoki, Makoto Kobayashi et al
www.sciencedirect.com/science/arti...
November 10, 2023 at 5:01 PM
#DBfeature #Zebrafish🐟 #EHT
LSD1 promotes the egress of hematopoietic stem and progenitor cells into the bloodstream during the endothelial-to-hematopoietic transition
by Junya Tamaoki, Makoto Kobayashi et al
www.sciencedirect.com/science/arti...
LSD1 promotes the egress of hematopoietic stem and progenitor cells into the bloodstream during the endothelial-to-hematopoietic transition
by Junya Tamaoki, Makoto Kobayashi et al
www.sciencedirect.com/science/arti...
Meme kanserinde bağışıklık sisteminden kaçışın anlaşılması tedavi yolunun bulunmasını sağlayabilir.3 farklı protein CDK9, RNF20 ve LSD1 arasındaki zincirleme reaksiyonun meme kanseri hücrelerinin bağışıklık sisteminden kaçmasına yardımcı olduğu öne sürülmüş.
www.research.uky.edu/news/markey-...
www.research.uky.edu/news/markey-...
March 13, 2024 at 11:08 AM
Meme kanserinde bağışıklık sisteminden kaçışın anlaşılması tedavi yolunun bulunmasını sağlayabilir.3 farklı protein CDK9, RNF20 ve LSD1 arasındaki zincirleme reaksiyonun meme kanseri hücrelerinin bağışıklık sisteminden kaçmasına yardımcı olduğu öne sürülmüş.
www.research.uky.edu/news/markey-...
www.research.uky.edu/news/markey-...